Quotient Bioresearch Ltd. has acquired Charles River Laboratories’ Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient. The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, which Quotient acquired in December 2008, to form a new strategic business unit within Quotient. The group will be known as Quotient Clinical. The Edinburgh clinical unit will combine with Pharmaceuti...